Physician profile
Jon G Thomas
NPI 1437209434
$1,713.17
in general payments reported to CMS, 2019-2025
30 companies · $83.51 in 2025
The $83.51 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $405 · 2021: $371 · 2022: $118 · 2023: $119 · 2024: $27.58 · 2025: $83.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $230.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $289.67 | 2019-2025 | Qulipta, Ubrelvy |
| Amgen INC. | $195.26 | 2019-2021 | |
| Boston Scientific Corporation | $136.45 | 2020-2021 | |
| Novo Nordisk INC | $135.45 | 2019-2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.03 | 2019-2021 | |
| Insulet Corporation | $92.06 | 2019-2020 | |
| Astellas Pharma US INC | $84.50 | 2019-2023 | Veozah |
| Amarin Pharma, INC. | $72.08 | 2019-2021 | |
| Abbott Laboratories | $56.76 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $51.11 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $50.22 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.13 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.70 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $37.17 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $35.67 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $28.97 | 2021 | |
| Vanda Pharmaceuticals INC. | $27.87 | 2025 | Hetlioz, Fanapt |
| Kowa Pharmaceuticals America, INC. | $25.11 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $25.11 | 2019-2020 | |
| Mannkind Corporation | $23.92 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.43 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.04 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $18.01 | 2021 | |
| Genentech USA, INC. | $14.00 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.52 | 2019 | |
| Shire North American Group INC | $12.58 | 2019 | |
| Scilex Pharmaceuticals INC. | $12.38 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.79 | 2019 | |
| Dexcom, INC. | $11.73 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.